野村发表报告指，下调国药控股(01099.HK) 2024年及今年的销售预测各1.4%，并减其盈利预测分别5.3%及5.3%，以将毛利压力及信贷损失/减值纳入考虑。该行维持国药“买入”评级，将目标价由28.46元降至25.09元。
该行料公司去年第四季收入按年跌0.4%，盈利按年跌2.8%。而从毛利角度，该行料期内毛利会收窄0.5个百分点至8.4%、经润毛利会跌0.4个百分点至3.3%，加上利息支出较低，预期公司上季赚29亿元人民币，按年跌2.8%，意味去年盈利为82亿元人民币，按年下滑9.9%。(vc/w)
(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.